Financial Performance - WeRide reported Q2 2025 revenue of US$17.8 million, representing a 60.8% year-on-year increase [8] - Robotaxi revenue surged 836.7% year-on-year to US$6.4 million, contributing 36.1% of total revenue, the highest concentration since 2021 [2][8] - Gross profit increased by 40.6% year-on-year, indicating steady growth [2][8] Commercialization Progress - WeRide's Robotaxi fleet in Abu Dhabi has tripled since December 2024, maintaining the largest fleet outside the US and China [3][9] - The company has achieved over 2,200 days of safe Robotaxi operations, setting an industry safety benchmark [3] - Plans to expand the Robotaxi fleet to hundreds and extend operations into additional areas of Abu Dhabi in 2025 [9] Technology Breakthroughs - WeRide launched the HPC 3.0 high-performance computing platform, developed with Lenovo and powered by NVIDIA's DRIVE AGX Thor chips [15] - The Robotaxi GXR became the world's first mass-produced Level 4 autonomous vehicle built on NVIDIA DRIVE AGX Thor chips [16] - The automotive-grade HPC 3.0 platform reduces the cost of the autonomous driving suite by 50% [16] Management Commentary - The CEO highlighted the rapid growth of the Robotaxi business as a reflection of the company's strategic vision and strong partnerships [15] - The CFO noted that the strong topline performance is driven by the increasing contribution from the Robotaxi business, indicating improved unit economics and commercial viability [15]

Core Financial Performance - Mission Valley Bancorp reported net income of $1.2 million, or $0.37 per diluted share, for Q2 2025, a decrease from $2.0 million, or $0.60 per diluted share, in Q2 2024 [1] - For the six months ended June 30, 2025, net income was $2.8 million, or $0.84 per diluted share, compared to $3.7 million, or $1.10 per diluted share, for the same period in 2024 [1] Revenue and Income Breakdown - Net Interest Income for Q2 2025 was $7.5 million, an increase of $0.8 million, or 11.94%, compared to Q2 2024 [7] - Non-Interest Income decreased to $2.2 million in Q2 2025, down $0.7 million, or 24.14%, from Q2 2024 [7] - The company sold $14.3 million in SBA loans in Q2 2025, resulting in a gain on sale of $0.7 million, compared to $21.7 million in SBA loans sold and a gain of $1.1 million in Q2 2024 [7] Asset and Deposit Growth - Total Assets increased to $740.6 million as of June 30, 2025, up $63.3 million, or 9.35%, from December 31, 2024 [7] - Gross Loans rose to $594.9 million as of June 30, 2025, an increase of $47.9 million, or 8.76%, compared to December 31, 2024 [7] - Total Deposits reached $599.4 million as of June 30, 2025, up $48.1 million, or 8.72%, from December 31, 2024 [7] Asset Quality and Credit Losses - The company reported $35 thousand in net charge-offs in Q2 2025, compared to $12 thousand in net recoveries in Q2 2024 [7] - Past Due Loans decreased to $4.9 million as of June 30, 2025, from $5.3 million as of December 31, 2024 [7] - The Allowance for Credit Losses was $8.3 million, or 1.39% of Gross Loans, as of June 30, 2025, compared to $8.1 million, or 1.48% of Gross Loans, as of December 31, 2024 [7] Capital and Liquidity Position - The Common Equity Tier 1 Capital Ratio was 9.94%, Tier 1 Capital ratio was 10.85%, Total Risk Based Capital Ratio was 12.10%, and Leverage Ratio was 9.79% as of June 30, 2025 [10] - Available borrowing capacity decreased to $171.5 million as of June 30, 2025, down $37.2 million, or 17.82%, from December 31, 2024 [10] Strategic Initiatives - The company experienced core deposit growth due to initiatives started last year and plans to open a new full-service branch in Arcadia, California, targeting late Q3 or early Q4 2025 [2]

Core Viewpoint - GenScript Biotech Corporation has received an upgraded ESG rating of AA from MSCI, reflecting its strong commitment to sustainability and responsible business practices in the biotech industry [1][2][3]. Group 1: ESG Rating and Recognition - The AA rating from MSCI positions GenScript as a global leader in ESG, highlighting its excellence in product safety, quality, and human capital development [1][2]. - GenScript's sustainability initiatives have been recognized through various accolades, including a Silver Medal from EcoVadis and inclusion in the FTSE4Good Index Series [3]. Group 2: Commitment to Sustainability - The company is a participant in the United Nations Global Compact, adhering to principles on human rights, labor, environment, and anti-corruption [3]. - GenScript's carbon reduction targets have been validated by the Science Based Targets initiative (SBTi), showcasing its commitment to combating climate change [3]. Group 3: Company Overview - Founded in 2002, GenScript Biotech Corporation employs over 5,500 individuals and has served more than 200,000 customers across 100 countries [4]. - The company's mission is to enhance health for people and nature through biotechnology, positioning it as a trusted global leader in the industry [4].

WEST PALM BEACH, Fla. , July 31, 2025 /PRNewswire/ -- Elliott Investment Management L.P. ("Elliott") today released the following statement on behalf of Partner John Pike and Portfolio Manager Bobby Xu regarding Rakesh Gangwal's decision to step down from his role as Chair at Southwest Airlines Co. (NYSE: LUV) (the "Company" or "Southwest"):We thank Mr. Gangwal for his leadership and contributions as Southwest's independent Chair during a transformational period for the company and we are grateful that he w ...

ORLANDO, Fla., July 31, 2025 /PRNewswire/ -- M-tron Industries, Inc. (NYSE American: MPTI) ("Mtron" or the "Company"), a U.S.-based supplier of radio frequency components and solutions to the aerospace & defense, avionics and space industries, will report financial results for the second quarter ended June 30, 2025, after the market closes on Tuesday, August 12, 2025. Mtron's press release will be available on the Investor Relations website at ir.mtron.com.Mtron will also host a conference call on Wednesday ...

NEW YORK, July 31, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) between September 17, 2024 and May 26, 2025, both dates inclusive (the "Class Period"), of the important August 11, 2025 lead plaintiff deadline.So what: If you purchased Rocket Pharmaceuticals securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingenc ...

Second Quarter 2025 Renewables SBU Adjusted EBITDA Grew 56% Versus Second Quarter 2024Strategic Accomplishments On track to add 3.2 GW of new projects in operation in 2025 1.9 GW already completed Remaining 1.3 GW 78% complete Since the first quarter call in May, signed or awarded new long-term PPAs for 1.6 GW of solar and wind, all with data center companies PPA backlog of 12 GW, including 5.2 GW under construction AES Indiana filed a petition for regulatory rate review with the Indiana Utility Regulator ...

Transaction is the Largest for an Office Property in Dallas Year-to-Date1DALLAS, July 31, 2025 /PRNewswire/ -- Newmark Group, Inc. (Nasdaq: NMRK) ("Newmark" or "the Company"), a leading commercial real estate advisor and service provider to large institutional investors, global corporations, and other owners and occupiers, announces the Company has arranged the $218 million sale of The Link at Uptown, a recently delivered Class AA office tower in the Uptown submarket of Dallas, Texas. Vice Chairmen Chris Mu ...

SAN DIEGO, July 31, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Lockheed Martin Corporation (NYSE: LMT) securities between January 23, 2024 and July 21, 2025. Lockheed Martin is an aerospace defense company.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The Allegations: Robbins LLP is Investigating Allegations that Lockheed Martin Corporation (LMT) Mis ...

MORTON GROVE, Ill., July 31, 2025 /PRNewswire/ -- Lifeway Foods, Inc. (NASDAQ: LWAY) ("Lifeway" or "the Company"), a leading supplier of kefir and fermented dairy products, is proud to announce it has been named Processor of the Year by Dairy Foods Magazine – the publication's highest annual honor recognizing innovation, leadership, growth and impact in the dairy industry. The Lifeway Foods team at Natural Products Expo West 2025 This prestigious award highlights Lifeway's exceptional performance in 20 ...